Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
60.56
+0.20 (0.33%)
Sep 1, 2026, 11:51 AM EDT - Market open
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $267.95M in the quarter ending June 30, 2026, a decrease of -40.73%. This brings the company's revenue in the last twelve months to $874.09M, down -7.41% year-over-year. In the year 2025, Ionis Pharmaceuticals had annual revenue of $943.71M with 33.83% growth.
Revenue (ttm)
$874.09M
Revenue Growth
-7.41%
P/S Ratio
11.48
Revenue / Employee
$590,603
Employees
1,480
Market Cap
10.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 943.71M | 238.57M | 33.83% |
| Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
| Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
| Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
| Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
| Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
| Dec 31, 2019 | 1.12B | 522.93M | 87.20% |
| Dec 31, 2018 | 599.67M | 85.50M | 16.63% |
| Dec 31, 2017 | 514.18M | 141.40M | 37.93% |
| Dec 31, 2016 | 372.78M | 89.07M | 31.40% |
| Dec 31, 2015 | 283.70M | 69.54M | 32.47% |
| Dec 31, 2014 | 214.16M | 66.88M | 45.41% |
| Dec 31, 2013 | 147.29M | 45.24M | 44.33% |
| Dec 31, 2012 | 102.05M | 2.96M | 2.99% |
| Dec 31, 2011 | 99.09M | -9.39M | -8.65% |
| Dec 31, 2010 | 108.47M | -13.13M | -10.80% |
| Dec 31, 2009 | 121.60M | 14.41M | 13.44% |
| Dec 31, 2008 | 107.19M | 48.85M | 83.72% |
| Dec 31, 2007 | 58.34M | 43.49M | 292.65% |
| Dec 31, 2006 | 14.86M | -13.48M | -47.57% |
| Dec 31, 2005 | 28.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bio-Techne | 1.22B |
| Axsome Therapeutics | 776.57M |
| Krystal Biotech | 440.48M |
| Protagonist Therapeutics | 281.99M |
| Kymera Therapeutics | 105.00M |
| Cytokinetics | 67.67M |
| Crinetics Pharmaceuticals | 42.16M |
| Praxis Precision Medicines | 7.46M |
IONS News
- 4 days ago - Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data - TheFly
- 12 days ago - Ionis announces new data in sHTG to be presented at ESC Congress 2026 - TheFly
- 12 days ago - Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 - Business Wire
- 13 days ago - BMO Capital starts Ionis at Market Perform pending better visibility - TheFly
- 13 days ago - Ionis Pharmaceuticals initiated with a Market Perform at BMO Capital - TheFly
- 23 days ago - IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Business Wire
- 4 weeks ago - Ionis Pharmaceuticals price target raised to $76 from $72 at JPMorgan - TheFly
- 4 weeks ago - Ionis Pharmaceuticals price target raised to $93 from $90 at BofA - TheFly